ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)
Shots:
- ABL Bio has entered into a global licensing agreement with GSK for its Grabody-B BBB shuttle platform to develop therapies targeting various novel pathways using antibodies, siRNA, & ASOs for neurodegenerative diseases
- As per the deal, GSK will handle preclinical & clinical activities, manufacturing, & marketing of the potential programs in exchange for ~$99.4M, incl. $49.6M upfront, research milestones & potential expansion fee, with ~$2.67B in R&D, regulatory & marketing milestones, plus net sales-based tiered royalties, while ABL Bio will handle tech transfer
- Grabody-B targets IGF1R to overcome the BBB, improving drug penetration & allowing efficient drug delivery in the brain
Ref: Prnewswire | Image: ABL Bio & GSK
Related News:- ABL Bio Collaborates with Merck to Develop ABL103 Plus Keytruda for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
